News | February 09, 2009

Paclitaxel Stents Shown to be Effective in Treating Bypass Vein Grafts

February 9, 2009 - Implantation of drug-eluting stents to treat degenerative in aortocoronary saphenous vein graft (SVG) lesions is safe, according to a study published in the Jan. 15 issue of the American Journal of Cardiology (Vol. 103, issue 2, Pages 199-202).

The Paclitaxel-Eluting Stent Long-Term Outcomes in Percutaneous Saphenous Vein Graft Interventions (PELOPS) Study by researchers at the Cardiac Medical Unit of Grantham Hospital and the Department of Medicine at Queen Mary Hospital, both in Hong Kong, said paclitaxel-eluting stents in SVGs showed an association with low late loss, angiographic restenosis, and MACE at one-year follow-up.

Sixty-eight consecutive patients with 90 nonoccluded SVG lesions were treated with a Taxus stents ranging in size from 2.25 to 4.5 mm. Angiographic follow-up was performed on 63 patients (93 percent) and 83 lesions (92 percent) at 12 months. Researchers said major adverse cardiac event (MACE) was recorded in all patients at one year. The mean age of patients was 71 with predominance of men (75 percent). Glycoprotein IIb/ IIIa inhibitors were given in 21 patients (31 percent). Embolic protection devices were used in 54 lesions (60 percent). On average, patients received 1.4 stents per lesion with a stent size of 3.4 ± 0.6 mm and a length of 35.8 ± 27 mm.

Angiographic follow-up revealed a late loss of 0.36 ± 0.66 mm with an in-segment binary restenosis rate of 7 percent. The in-hospital MACE was 7 percent, which was solely contributed by 5 patients with postprocedure non–Q myocardial infarction. The one-year MACE was 15 percent, accounted by one noncardiac death and nine patients with target vessel revascularization. Peripheral vascular disease and the use of glycoprotein IIb/ IIIa inhibitors were the independent predictors of MACE at one year, the researchers said.

For more information:

Related Content

Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...
Abbott's Xience Sierra Stent Receives FDA Approval
Technology | Stents Drug Eluting | May 25, 2018
Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience Sierra, the newest...
Medtronic Launches 2 mm Onyx DES
Technology | Stents Drug Eluting | February 26, 2018
February 26, 2018 – Designed specifically for small vessels, Medtronic plc announced U.S.
Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently beca
Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting | January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or b
Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting | December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting | November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Overlay Init